CorMedix Inc. (CRMD)Healthcare | Biotechnology | Parsippany, United States | NasdaqGM
7.39 USD
+0.26
(3.647%)
⇧
(April 17, 2026, 3:40 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:45 p.m. EDT
CRMD appears to be in a consolidating phase with mixed signals from options activity. While the recent price action shows a slight upward trend, the overall fundamentals and forecasting model stats suggest limited short-term momentum. The stock's low dividend yield and lack of historical dividends make it less attractive for income-focused investors. Long-term investors should consider the company's fundamentals and potential for growth, but the current market conditions and low IV suggest caution. Overall, it's a neutral to slightly bearish outlook for both short and long-term investors. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.078894 |
| AutoARIMA | 0.099396 |
| AutoETS | 0.099396 |
| AutoTheta | 0.136065 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 56% |
| H-stat | 2.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.625 |
| Excess Kurtosis | -0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 36.741 |
| Revenue per Share | 4.327 |
| Market Cap | 584,182,400 |
| Trailing P/E | 3.62 |
| Forward P/E | 10.26 |
| Beta | 1.41 |
| Profit Margins | 52.31% |
| Website | https://cormedix.com |
As of April 11, 2026, 2:45 p.m. EDT: Options activity indicates mixed sentiment. Calls show increased positioning in out-of-the-money strikes, suggesting potential for upward movement, while puts show significant interest in strikes below the current price, indicating caution. The IV (Implied Volatility) is generally low, suggesting limited expected price movement. However, the presence of high open interest in certain strikes suggests that traders are anticipating volatility, possibly due to upcoming earnings or corporate updates.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.12407863 |
| Address1 | 389 Interpace Pkwy |
| Address2 | Suite 450 |
| All Time High | 52.0 |
| All Time Low | 0.75 |
| Ask | 7.42 |
| Ask Size | 6 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 965,610 |
| Average Daily Volume3 Month | 1,653,259 |
| Average Volume | 1,653,259 |
| Average Volume10Days | 965,610 |
| Beta | 1.408 |
| Bid | 5.33 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 5.114 |
| City | Parsippany |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.39 |
| Current Ratio | 2.106 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.44 |
| Day Low | 7.05 |
| Debt To Equity | 36.741 |
| Display Name | CorMedix |
| Dividend Date | 1,553,558,400 |
| Earnings Call Timestamp End | 1,772,717,400 |
| Earnings Call Timestamp Start | 1,772,717,400 |
| Earnings Growth | -0.283 |
| Earnings Quarterly Growth | 0.041 |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | 174,890,000 |
| Ebitda Margins | 0.56106997 |
| Enterprise To Ebitda | 3.225 |
| Enterprise To Revenue | 1.809 |
| Enterprise Value | 564,012,288 |
| Eps Current Year | 0.79 |
| Eps Forward | 0.72 |
| Eps Trailing Twelve Months | 2.04 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.9754 |
| Fifty Day Average Change | 0.4145999 |
| Fifty Day Average Change Percent | 0.059437435 |
| Fifty Two Week Change Percent | -12.407864 |
| Fifty Two Week High | 17.43 |
| Fifty Two Week High Change | -10.040001 |
| Fifty Two Week High Change Percent | -0.5760184 |
| Fifty Two Week Low | 6.13 |
| Fifty Two Week Low Change | 1.2599998 |
| Fifty Two Week Low Change Percent | 0.20554645 |
| Fifty Two Week Range | 6.13 - 17.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,273,757,400,000 |
| Float Shares | 68,064,762 |
| Forward Eps | 0.72 |
| Forward P E | 10.263888 |
| Free Cashflow | 108,508,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 191 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.92914003 |
| Gross Profits | 289,620,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.079780005 |
| Held Percent Institutions | 0.56008 |
| Implied Shares Outstanding | 79,050,395 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-02 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,553,558,400 |
| Last Split Factor | 1:5 |
| Long Business Summary | CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey. |
| Long Name | CorMedix Inc. |
| Market | us_market |
| Market Cap | 584,182,400 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_79611048 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 162,067,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 563,660,936 |
| Number Of Analyst Opinions | 7 |
| Open | 7.27 |
| Operating Cashflow | 175,046,000 |
| Operating Margins | 0.53902 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 908 517 9500 |
| Previous Close | 7.13 |
| Price Eps Current Year | 9.35443 |
| Price Hint | 2 |
| Price To Book | 1.4450529 |
| Price To Sales Trailing12 Months | 1.8741275 |
| Profit Margins | 0.5231 |
| Quick Ratio | 1.835 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | 0.25999975 |
| Regular Market Change Percent | 3.6465602 |
| Regular Market Day High | 7.44 |
| Regular Market Day Low | 7.05 |
| Regular Market Day Range | 7.05 - 7.44 |
| Regular Market Open | 7.27 |
| Regular Market Previous Close | 7.13 |
| Regular Market Price | 7.39 |
| Regular Market Time | 1,776,454,823 |
| Regular Market Volume | 945,846 |
| Return On Assets | 0.21209 |
| Return On Equity | 0.66558 |
| Revenue Growth | 3.121 |
| Revenue Per Share | 4.327 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 79,050,395 |
| Shares Percent Shares Out | 0.1997 |
| Shares Short | 15,782,505 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 16,618,186 |
| Short Name | CorMedix Inc. |
| Short Percent Of Float | 0.2016 |
| Short Ratio | 9.62 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CRMD |
| Target High Price | 19.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 14.57143 |
| Target Median Price | 14.0 |
| Total Cash | 148,531,008 |
| Total Cash Per Share | 1.879 |
| Total Debt | 148,914,000 |
| Total Revenue | 311,708,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.04 |
| Trailing P E | 3.622549 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.05675 |
| Two Hundred Day Average Change | -2.6667504 |
| Two Hundred Day Average Change Percent | -0.2651702 |
| Type Disp | Equity |
| Volume | 945,846 |
| Website | https://cormedix.com |
| Zip | 7,054 |